



Barcode

GENETIC TEST REQUISITION FORM

Test Code: **SLS160004** Test Name: **Colorectal Cancer Comprehensive Panel** TR ID:
 Test Code: Test Name: TR ID:
 Test Code: Test Name: TR ID:
 Test Code: Test Name: TR ID:

PATIENT DETAILS

Patient MRN/UHID #:
 Patient Name: **Mr. Sahabeen Safan** DOB: Age: **40** Sex: **M**
 Marital Status: Nationality: Contact No.:
 Address:
 Email ID: Pincode:
 ID Proof: Driving License Aadhaar Card Voter ID card Ration card Others: _____

ADDITIONAL DETAILS IF REQUIRED

Transfusion Date (if available): Blood Group:

CLINICIAN INFORMATION

Referring Clinician: **Dr.A. Iqbal** Clinician Contact:
 Referring Hospital:
 Email Id:
 Address:
 Address:

ADDITIONAL FAMILY MEMBERS' DETAILS

Disease Status - Affected: Age at Diagnosis:
 Affected Sibling/Family members: Yes No (If yes, provide the details in the table below)

Name	Relation with Patient	Type of cancer	Age at Diagnosis	Sex

SAMPLE COLLECTION INFORMATION

Date & Time of Collection: Sample collected by:
 Clinical History/Pathology Report Attached: H and E Slides sent:

FOR OFFICIAL USE ONLY

Region: Bill type (for internal use only):
 Sales person: GC done by: GC date:

PEDIGREE / FAMILY HISTORY / CLINICAL HISTORY (TO BE FILLED BY CLINICIAN / GENETIC COUNSELOR)

Not Available

(PLEASE ATTACH SEPARATELY INCASE OF DETAILED PEDIGREE)

DETAILS OF SAMPLE SENT TO THE LAB

SEND SAMPLES TO
(Monday to Saturday only)

Strand Life Sciences Pvt. Ltd.
Ground Floor, UAS Alumni Association Building,
Veterinary College Campus, Hebbal, Bangalore-560024
Phone: +91 99 8044 8044, E-mail: support.strandx@strandls.com

INFORMED CONSENT FOR GENETIC TESTING

- If the proband is over 18 years of age, 'You' in this form refers to the proband
- If the proband is a minor or differently-abled, 'You' in this form refers to the Legal Guardian of the proband
- 'We', 'Our', 'Us' refers to Strand Life Sciences Pvt. Ltd.

You hereby consent to undergo testing offered by us and understand that:

1. Your biological sample(s) will be collected using generally accepted techniques. The sample(s) could be blood, saliva, tumor tissue, or any other biological sample as needed.
2. You understand that the sample(s) may be used to determine if you and/or your family members have variants in your gene(s). Results may indicate affected status, increased risk of being affected in future, inherited risk of disease, somatic mutations in tumor tissue, or other such findings.
3. Genetic tests are relatively new and are being improved and expanded continuously. You are aware of the risks and limitations of genetic testing.
4. You may need to share your relevant health records to correlate the findings from the genetic testing.
5. The genetic test report will be usually released within the Turnaround Time (TAT) specified by us for the test.
6. A positive test result is an indication that the individual being tested has a genomic variant that might have implications for their health or their progeny's health. Consultation may be sought from any physician or genetic counselor of your choice. You may also consider independent testing and consultation in addition.
7. The report will be shared with your authorized physician where applicable, or shared to your registered email ID, or shared on our secure portal, or a hard copy of the report can be shared upon request to the address provided in this form.
8. It is possible that knowledge of genetic information of an individual might be misused if it is in the wrong hands. Hence, we cannot reveal the genetic information even to family members without your explicit written authorization to do so. We will maintain complete confidentiality of the test results, as genetic test results can have social implications.
9. Genetic testing has its limitations. A repeat or alternative tests might be recommended by your treating physician accordingly.
10. Genetic testing might identify secondary findings in genes outside of the original test genes as defined by the American College of Medical Genetics. You can opt out from receiving secondary findings by ticking this box here.
11. All laboratory raw data are confidential and will not be released unless a special written request is made by you or the consulting clinician on record, or a valid court order is received by us. VCF, FASTQ and BAM files can be provided to you

- or your authorized personnel for a period of 3 months. For requests beyond that period we may charge an additional cost, as per institutional policy.
12. Our laboratory does not return any leftover sample after completion of testing under any circumstances. The only exception to the above is in the case of FFPE tumor blocks which can be returned upon request by you or your ordering physician within a period of 6 months. Any left over DNA (if available), regardless of the sample type, can be requested by you for up to a period of 3 months, provided you bear the transportation costs.
 13. Samples collected as part of routine care with potential for future genetic research will be stored by our laboratory in accordance with ICMR guidelines 2017, clause 10.3.7.
 14. Samples can also be shared with collaborators within or outside the country in line with existing relevant guidelines, in accordance with ICMR guidelines 2017, clause 10.3.8.
 15. You understand and agree to the use of your data and biological sample for future research by us and our collaborators. We will use your samples and data in anonymised or aggregated form, such that it will be incapable of identifying you. By voluntarily signing this consent form you agree to provide broad or blanket consent for the storage and use of your samples and data as specified by ICMR guidelines 2017. You can opt out of this clause by ticking this box here.
 16. Sharing of data with our collaborators will be bound under a data access agreement that will maintain individual confidentiality. Your personal identity will not be revealed in any information shared with third parties or published; your data will be coded accordingly.
 17. The future use of your data or sample in research may result in commercial gains. Based on the nature of research outcomes, further investments by us may be needed to commercialize these outcomes. You will not have the right to participate in any direct monetary gains resulting from any future commercial activity.
 18. You understand and agree to being re-contacted in the future if there is new information available on your genomic variants or new research envisaged that you could benefit from.
 19. You have the full rights to decide whether or not you wish to provide consent, nobody can coerce you into providing consent. You can also choose to withdraw your consent at a later stage if you so wish, you need to notify us regarding the same.
 20. In case you have any concerns or perceive any conflict of interest, you may seek clarification on institutional policy from relevant authorities.

Name of Individual/Legal Guardian: **Mr. Sahabeen Safan**

Date: **7/9/2024**


Signature: 

STATEMENT OF PHYSICIAN/GENETIC COUNSELOR

- I have explained the genetic testing suitable for this individual and the individual has had the opportunity to ask questions.
- I have addressed the limitations outlined above, and I have answered this person's questions.
- I have obtained consent from the patient or the legal guardian for this testing. I confirm that the individual has given consent willingly.
- I allow Strand Life Sciences to contact the aforementioned patient for clinical history, treatment plan, and other details relevant to this test.
- I undertake to maintain the privacy and confidentiality of the patient's genetic data obtained from Strand Life Sciences and will remain solely responsible for any wrongful acts and/or omissions arising out of, or in relation to my use of the patient's genetic data.

Name: **Dr. Mahendra Perera**

Date:

(Physician/Genetic Counselor) Signature: 



Mediland Hospital

Regd. No : PHSRC/PH/113 619, Main street, Kalmunai - 09. Tel : 067 2222336, 067 2220306

Mr. Sahabdeen Safan 40yrs,

31/08/2024

Aegle omics

33, park road

Colombo - 02.

Δ CA Colon

Surgery done

HP - poorly differentiated Adeno ca (G3)

LN 0/30

Findings more favour for MMR deficient

Ix Request - (MLH1, PMS2, MSH2 & MSH6)

Sample - Paraffin block.

Full Histopathology

Jhonny

DR. JOBAL (MBBS, MD, MBA)
SCE in Medical Oncology (RCP/UK)
Consultant Clinical Oncologist
Teaching Hospital
Batticaloa.

Mediland Pharmacy & Mega Laboratory Service

Tel & Fax : 067 2225390 Lab : 076 3700022



BIO-RAD

CONFIDENTIAL LABORATORY REPORT


PATIENT NAME : MR. SAHABDEEN SAFAN
AGE : 40 YEARS GENDER : MALE
BILL NO : EH219238 LAB REF NO : 24KH 0028549
OPD / IP : IP WARD : ICU
REFERRED BY : PROF. KEMAL I DEEN
COLLECTED TIME : 2024-05-28 08:41 REPORTED TIME : 2024-06-08 12:41

TEST : HISTOPATHOLOGY

Specimen : A) Right side hemicolectomy
B) Proximal stapled doughnut
C) Distal stapled doughnut

Macroscopy : A) Ileum - 20mm, caecum and colon - 380mm.
Proximal margin - 80mm. Distal margin - 25mm.
Appendix - 75mm. There is a stricturing lesion 30mm in length, located 45mm from the ileocaecal valve and 65mm from the proximal end resection margin.
Cut surface of tumour shows infiltration into the pericolic fat. Tumour to pericolic resection margin is 50mm. The
23 lymph nodes retrieved (Apical 2, periileocaecal - 21 and - the largest lymph node measures 10mm.
B) Proximal doughnut - Piece of bowel measuring 15 x 10 x 8mm. Bisected.
C) Distal doughnut - Piece of bowel measuring 15 x 10 x 5mm.

Key to blocks : A1) - Proximal end resection margin
A2) - Distal end resection margin
A3) - Appendix
A4-A6) - Tumour to serosal surface
A7-A9) - Tumour to pericolic fat
A10) - Apical lymph nodes
A11) - Largest lymph node (bisected)
A12-A13) - Lymph node (bisected)
A14) - Apical 0/2 lymph nodes.
A15-21) - Lymph nodes
A22) - ? non regional lymph node


(Page 01/03)



CONFIDENTIAL LABORATORY REPORT

PATIENT NAME	: MR. SAHABDEEN SAFAN	GENDER	: MALE
AGE	: 40 YEARS	LAB REF NO	: 24KH 0028549
BILL NO	: EH219238	WARD	: ICU
OPD / IP	: IP	REPORTED TIME	: 2024-06-08 12:41
REFERRED BY	: PROF. KEMAL I DEEN		
COLLECTED TIME	: 2024-05-28 08:41		

TEST : **HISTOPATHOLOGY**

Microscopy

: These are sections of a poorly differentiated adenocarcinoma exhibiting only a vague glandular pattern (High grade - G3). The tumour margins are broad and pushing in type with tumour infiltrating lymphocytes blunting the tumour margins (peritumoral) and making assessment of tumour budding difficult.

The tumour infiltratesw through the bowel wall in large cell islands and into the subserosa and pericaecal fat. Through the tumour is close to the serosal surface (< 1mm away) no serosal involvement is demonstrable - pT3. No lymphatic vascular or perineural invasion is present. - LO V0 pN0.

There are no lymphoid aggregates at the tumour borders to denote a significant host lymphoid response but peritumoural tumour infiltrating lymphocytes are evident. There is no evidence of a synchronous bowel pathology. The end resection margin and the pericaecal circumferential margin are not involved. None of the 30 lymph nodes identified (0/2 apical lymph nodes, 0/7-lymph nodes adjacent to tumour blocked with the tumour margins 0/21 - lymph nodes retrieved from the ileocaecal fat) contain metastasis - pN0.

Both the proximal doughnut (A) and distal doughnut (B) are histologically normal.

Comment

: The tumour morphology suggests the possibility of mismatch repair gene deficient colonic carcinoma. Therefore investigations of MMR gene defects (MLH1, PMS2, MSH2 and MSH6 the basic panel of MMR gene markers) are recommended.

24/8/2024 . Dear Tanuki,

Please could we proceed with MMR gene defect identification . Thanks *PK* K Deen .

Signature
(Page 02/03)



CONFIDENTIAL LABORATORY REPORT

PATIENT NAME : MR. SAHABDEEN SAFAN
AGE : 40 YEARS GENDER : MALE
BILL NO : EH219238 LAB REF NO : 24KH 0028549
OPD / IP : IP WARD : ICU
REFERRED BY : PROF. KEMAL I DEEN
COLLECTED TIME : 2024-05-28 08:41 REPORTED TIME : 2024-06-08 12:41

TEST : **HISTOPATHOLOGY**

Conclusion : Right side hemicolectomy specimen

Poorly differentiated adenocarcinoma (High grade - G3
? MMR deficient colonic carcinoma.

pT3 pN0

L0 V0 pN0

No tumour budding

No synchronous bowel pathology


Resection margins are free of tumour

0/30 lymph nodes contain metastases - pN0

Proximal and distal doughnuts - Within normal limits.

Recommend testing for MMR deficiency.

JH - 1390/24


Prof. Janaki Hewavisenthi
MBBS, D. Path, MD (Histopathology)
Consultant Histopathologist

**** Blocks and slides of this specimen will be retained as follows;
Slides - Five years, Blocks - Ten years & Specimen - Three months from
the date of the report issued ****.





BIO-RAD

CONFIDENTIAL LABORATORY REPORT


PATIENT NAME : MR. SAHABDEEN SAFAN
AGE : 40 YEARS GENDER : MALE
BILL NO : EH219238 LAB REF NO : 24KH 0028549
OPD / IP : IP WARD : ICU
REFERRED BY : PROF. KEMAL I DEEN
COLLECTED TIME : 2024-05-28 08:41 REPORTED TIME : 2024-06-08 12:41

TEST : **HISTOPATHOLOGY**

Specimen : A) Right side hemicolectomy
B) Proximal stapled doughnut
C) Distal stapled doughnut

Macroscopy : A) Ileum - 20mm, caecum and colon - 380mm.
Proximal margin - 80mm. Distal margin - 25mm.
Appendix - 75mm. There is a stricturing lesion 30mm in length, located 45mm from the ileocaecal valve and 65mm from the proximal end resection margin.
Cut surface of tumour shows infiltration into the pericolic fat. Tumour to pericolic resection margin is 50mm. The
23 lymph nodes retrieved (Apical 2, periileocaecal - 21 and - the largest lymph node measures 10mm.
B) Proximal doughnut - Piece of bowel measuring 15 x 10 x 8mm.
Bisected.
C) Distal doughnut - Piece of bowel measuring 15 x 10 x 5mm.

Key to blocks : A1) - Proximal end resection margin
A2) - Distal end resection margin
A3) - Appendix
A4-A6) - Tumour to serosal surface
A7-A9) - Tumour to pericolic fat
A10) - Apical lymph nodes
A11) - Largest lymph node (bisected)
A12-A13) - Lymph node (bisected)
A14) - Apical 0/2 lymph nodes.
A15-21) - Lymph nodes
A22) - ? non regional lymph node


(Page 01/03)

